Marjolein Drent

Prof. Marjolein Drent

ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands
+2
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
ECElliott Crouser
Elliott Crouser
Lisa MaierLisa Maier
Lisa Maier
KWKevin C. Wilson
Kevin C. Wilson
CBCatherine A. Bonham
Catherine A. Bonham
AMAdam S. Morgenthau
Adam S. Morgenthau
RBRobert P. Baughman
Robert P. Baughman
Background: The diagnosis of sarcoidosis is not standardized but is based on three major criteria: a compatible clinical presentation, finding nonnecrotizing granulomatous inflammation in one or more tissue samples, and the exclusion of alternative causes of granulomatous disease. There are no universally accepted measures to determine if each diagnostic criterion has been satisfied; therefore, the diagnosis of sarcoidosis is never fully secure. Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize the best available evidence. The evidence was appraised using the Grading of Recommendations, Assessment, Development, and Evaluation approach and then discussed by a multidisciplinary panel. Recommendations for or against various diagnostic tests were formulated and graded after the expert panel weighed desirable and undesirable consequences, certainty of estimates, feasibility, and acceptability. Results: The clinical presentation, histopathology, and exclusion of alternative diagnoses were summarized. On the basis of the available evidence, the expert committee made 1 strong recommendation for baseline serum calcium testing, 13 conditional recommendations, and 1 best practice statement. All evidence was very low quality. Conclusions: The panel used systematic reviews of the evidence to inform clinical recommendations in favor of or against various diagnostic tests in patients with suspected or known sarcoidosis. The evidence and recommendations should be revisited as new evidence becomes available.

17 June 2021 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
RBRobert P. Baughman
Robert P. Baughman
DVDominique Valeyre
Dominique Valeyre
Peter KorstenPeter Korsten
Peter Korsten
Alexander MathioudakisAlexander Mathioudakis
Alexander Mathioudakis
WWWim Wuyts
Wim Wuyts
DODaniel R. Ouellette
Daniel R. Ouellette
Background: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations. Methods: A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations. Results: The Task Force committee delivered 12 recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac and neurologic disease as well as fatigue. One PICO question regarding small-fibre neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation. Conclusions: There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.

9 September 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
MDMarjolein Drent
Marjolein Drent
ECElliott D Crouser
Elliott D Crouser
JGJohan Grunewald
Johan Grunewald
Sarcoidosis is a lung disease of unknown cause characterized by noncaseating granulomas; the heart and nervous system may also be involved. It is often misdiagnosed; tissue biopsy is needed for a definitive diagnosis. Glucocorticoids are recommended as initial treatment, when needed, but not for long-term care.

22 March 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MDMarjolein Drent
Marjolein Drent
ELElyse E. Lower
Elyse E. Lower
JVJolanda De Vries
Jolanda De Vries
Sarcoidosis-associated fatigue is globally recognised as a disabling symptom. Fatigue has been reported in up to 50–70% of sarcoidosis patients, causing impaired quality of life. The aetiology of this troublesome problem remains elusive and is usually multifactorial. Fatigue can be a consequence of treatment itself, including as a complication of corticosteroid therapy. The diagnosis of sarcoidosis-associated fatigue requires an extensive evaluation to identify and treat potentially reversible causes. Granuloma formation and cytokine release may be involved in its aetiology. However, despite adequate sarcoidosis treatment, many patients continue to experience fatigue. Comorbidities associated with sarcoidosis, including depression, anxiety, hypothyroidism and altered sleep patterns, may all contribute to fatigue. Despite an exhaustive search for treatable clinical causes of fatigue, most patients’ complaints of fatigue are not correlated with clinical parameters of disease activity. Recent studies have demonstrated the effectiveness of various neurostimulants, including methylphenidate, for the treatment of sarcoidosis-associated fatigue. These and other agents may be useful adjuncts for the treatment of sarcoidosis-associated fatigue. Obviously, there is a need for studies evaluating the causes and new therapeutic options of sarcoidosis-associated fatigue. Psychological interventions should also be examined.

18 April 2014
Verified
Journal Article
Closed access
Marc JudsonMarc Judson
Marc Judson
UCUlrich Costabel
Ulrich Costabel
MDMarjolein Drent
Marjolein Drent
AWAthol U Wells
Athol U Wells
Lisa MaierLisa Maier
Lisa Maier
TIThe Wasog Sarcoidosis Organ Assessment Instrument Investigators
The Wasog Sarcoidosis Organ Assessment Instrument Investigators

1 December 2015 in Clinics in Chest Medicine
Verified
Journal Article
Closed access
MDMarjolein Drent
Marjolein Drent
BSBert Strookappe
Bert Strookappe
EHElske Hoitsma
Elske Hoitsma
JVJolanda De Vries
Jolanda De Vries